Hybrid Tomo-Helical and Tomo-Direct radiotherapy for localized prostate cancer

Sibel Karaca | Timur Koca | İsmail Hakkı Sarpün | Nina Tunçel | Aylin Fidan Korcum Şahin

Department of Radiation Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey

Correspondence
Sibel Karaca, Department of Radiation Oncology, Faculty of Medicine, Akdeniz University, Dumlupınar Boulevard, 07058 Campus, Antalya, Turkey.
Email:sibeltuzlaci@gmail.com

Abstract
Purpose: The aim of the study is to present a new planning approach to provide better planning target volume (PTV) coverage and reduce bladder and rectum dose with hybrid Tomo-Helical (TH)/Tomo-Direct (TD) radiotherapy (RT) for localized prostate cancer (LPC).

Methods: Twenty-five LPC patients were included in this retrospective study. TH plans, TD plans, and hybrid TH/TD plans were created. Lateral beams were used for the hybrid TD plan and the prescribed dose was 70 Gy in 28 fractions (hybrid plans were combined 45 Gy/18 fx for TH and 25 Gy/10 fx for TD). Doses of PTV (D2%, D98%, D50%, homogeneity index (HI), conformity index (CI), coverage) and organs at risk (OARs) (V50%, V35%, V25%, V5%, and V95%) were analyzed. The Wilcoxon signed-rank test was used to analyze the difference in dosimetric parameters. $p$-Value $< 0.05$ was considered statistically significant.

Results: TH plans showed better CI, and target coverage ($p < 0.01$) than TD and hybrid plans in all patient plan evaluations. However, TD plans D2%, D98%, and D50% doses were better than TH and hybrid plans. The HI values were similar between the three plans. Significant reductions in bladder and rectum V50%, V35%, and V25% doses ($p < 0.001$) were observed with hybrid plans compared to TH and TD. Penile bulb V95% and bowel V5% doses were better in the hybrid plans. Left and right femoral head V5% doses were higher in the hybrid plan compared to others ($p < 0.001$).

Conclusion: Concurrently hybrid TH/TD RT plan can be a good option to reduce the doses of the rectum and bladder in the RT of LPC.

KEYWORDS
hybrid radiotherapy, localized prostate cancer, Tomo-Direct, Tomo-Helical

1 INTRODUCTION

Prostate cancer is one of the most common types of cancer among men and primary radiotherapy (RT) is an established treatment option for patients with localized prostate cancer (LPC). Nowadays, LPC is treated with advances in RT such as intensity-modulated RT (IMRT) and image guide RT (IGRT) have helped to reduce toxicity. IMRT method allows dose escalation with high conformity and high dose to the prostate while sparing organs at risk (OAR) (rectum, bladder, bowel, and femoral heads). Studies on prostate cancer have shown that high-dose RT applications have significant contributions to treatment outcomes. However, the hypofraction program recently has been accepted as an external beam RT strategy in prostate cancer.
High-dose moderate hypofractionation RT is thought to reduce the effect of tumor cell repopulation\textsuperscript{12} and improve treatment outcomes in the RT of LPC.\textsuperscript{13–17}

Tomotherapy (Accuray Inc.) is an RT device with IGRT capability by taking daily Megavoltage Computed Tomography scan before treatment.\textsuperscript{18} Tomotherapy has different version treatment devices and one of them is TomoHDA. TomoHDA treatment system was produced after TomoTherapy-Hi-Art and TomoHD technologies. The first treatment with TomoHDA was performed at Center Oscar Lambret in Lille, France in 2013. TomoHDA system offers the user the chance to treat patients in two different modes. Tomo-Helical (TH) mode provides a continuous 360° beam that may result in optimal dose distribution and dose conformity.\textsuperscript{19} The TomoDirect (TD) mode is a non-rotational treatment option of the Tomotherapy platform and provides treatment at predetermined angles with a fixed gantry.\textsuperscript{20,21} TomoHDA provides faster and better dose distribution with the new technology IDMS (integrated data management system) with Precision Planning System.\textsuperscript{22}

In this study, we aimed to develop a new planning approach by creating simultaneous hybrid TH/TD treatment plans for LPC patients undergoing high-dose RT with TomoHDA. We intended to reduce the doses of OARs such as bladder and rectum by increasing target dose homogeneity with the hybrid technique.

2 | MATERIALS AND METHOD

2.1 | Patient selection and contouring

In this study, we used image data of 25 patients with a diagnosis of LPC. The patients who were treated for LPC using Elekta Synergy Platform linear accelerator and Tomotherapy HDA between June 2018 and September 2020, were retrospectively analyzed. The patients were instructed to drink 500–750 ml of water 45 min before the CT scan (as our clinical protocol). Patients were asked to empty their bladder before treatment and were provided to be treated with an empty rectum. Patients were placed in the head-first supine position and 2.5 mm slice thickness computed tomography (CT scan GE-Light Speed 64 Discovery RT 16 Slice; GE) was performed on the T-board in the supine arm up position. Magnetic resonance images were performed by a 3T whole-body system (Spectra; Siemens-HealthCare). Radiation oncologists contoured all targets and OARs of LPC patients. The whole prostate contoured as clinical target volume and planning target volume (PTV) generated by clinical target volume plus 5 mm posteriorly and 10 mm in other directions. Contouring of PTV and OARs were performed by using a CT scan with a 2.5 mm slice thickness and magnetic resonance images fusion. Rectum, bladder, bowel, femoral heads, and penile bulb were contoured as OARs. Rectum was contoured from ischial tuberosities to rectosigmoid flexure and femoral heads inferiorly to the bottom of ischial tuberosities. Urinary bladder contoured from its base to the dome and penile bulb contoured immediately inferior to the genitourinary diaphragm.\textsuperscript{23}

2.2 | Treatment planning

TH, TD, and hybrid TH/TD plans were created in the Tomotherapy HDA IDMS Precision Planning System (version 2.0.1.1[5]; Accuray Inc.) for each patient. All plans were normalized to cover 95% of the PTV, and 70 Gy delivered at Gy 2.5 Gy/fraction in 28 fractions.\textsuperscript{24} Various parameters can be used in the tomotherapy planning station optimization panel. One of the optimization parameters is the importance and the other one is the penalty. Critical organs are listed in order of priority. For the plans to be comparable, the same parameters (priority, importance, maximum dose penalties, and minimum dose penalties) were determined in both TH and TD plans (Table 1). A fine calculation grid (1.95 × 1.95 mm) was used for the final calculation process. Optimization resolution was selected as low. Each plan calculated the final dose after 200 iterations.

2.3 | Tomo-Helical, Tomo-Direct, and hybrid planning

The TD IMRT plans were generated with dynamic jaw mode. The field width, pitch, and modulation factor values were 2.5 cm, 0.251, and 2.0, respectively. Treatment plans were generated using a seven beams arrangement with gantry angles of 0°, 52°, 103°, 154°, 205°, 256°, and 308°. The prescribed dose was 70 Gy in 28 fractions.

The TH IMRT plans were generated with helical dynamic jaw mode. The field width, pitch, and modulation factor values were 2.5 cm, 0.314, and 2.0, respectively. The prescribed dose was 70 Gy in 28 fractions.

The hybrid tomotherapy plans were a combination of TH and TD plans. HD planning dose provided approximately two-thirds of the total dose. TD planning dose provided approximately one-third of the total dose. 25 Gy delivered at 2.5 Gy/fraction in 10 fractions. Seven lateral beams were used with gantry angles of 77°, 86°, 101°, 110°, 250°, 275°, and 300°. The prescribed dose was 45 Gy in 15 fractions and sum plans of TH/TD plans were determined.

2.4 | Dosimetric evaluation

Plan evaluations were based on dose–volume histogram (DVH) analysis. To evaluate the dose distribution
TABLE 1 Planning priority, importance, maximum (max) dose penalty, minimum (min) dose penalty, max dose, dose–volume histogram (DVH) volume (%), and DVH dose (Gy) for planning target volume (PTV) and organs at risk (OARs)

| Structures            | Overlap priority | Importance | Max dose (Gy) | Max dose penalty | DVH vol (%) | DVH dose (Gy) | Min dose (Gy) | Min dose penalty |
|-----------------------|-----------------|------------|---------------|-----------------|-------------|--------------|--------------|----------------|
| PTV                   | 1               | 100        | 70            | 100             | 95          | 70           | 70           | 100            |
| OARs                  |                 |            |               |                 |             |              |              |                |
| Bladder               | 1 (1 = highest priority) | 1          | 1             | 1               | 1           | 1            | 1            | 1              |
| Rectum                | 2               | 1          | 1             | 1               | 1           | 1            | 1            | 1              |
| Bowel                 | 3               | 1          | 1             | 1               | 1           | 1            | 1            | 1              |
| Right femoral head    | 4               | 1          | 1             | 1               | 1           | 1            | 1            | 1              |
| Left femoral head     | 5               | 1          | 1             | 1               | 1           | 1            | 1            | 1              |
| Penile bulb           | 6               | 1          | 1             | 1               | 1           | 1            | 1            | 1              |

of the target, parameters were calculated for PTVs: the absolute dose received by the 2% (D2%), the absolute dose received by the 50% (D50%), the absolute dose received by 98% (D98%; ICRU 83).25

Conformity index (CI) is the ratio of total tissue volume that receives the prescription isodose or more to the target volume that receives the prescription isodose:26

\[
CI = \frac{V_{RI}}{TV}
\]  

where \(V_{RI}\) is the volume covered by the prescribed dose and TV is the target volume.

Homogeneity index (HI) is the ratio of the maximum dose to the prescription dose:26

\[
HI = \frac{D_{max}}{D_p}
\]

where \(D_{max}\) is the maximum dose of the target volume and \(D_p\) is the prescription dose of the target volume.

Coverage is the volume of the tumor that receives the prescription dose divided by the total volume. For the bladder and rectum, the DVH points of V50(%), V35(%), V25(%), V20(%), and V15(%) were examined. Also, the doses of femoral heads V5(%), bowel V5(%), and penile bulb V95(%) were evaluated.

3 | RESULTS

In this study, we investigated whether there was a statistically significant difference in dosimetric values between the TH-TD, TH-hybrid TH/TD, and TD-hybrid TH/TD plans. Tables 2–4 summarize the DVH parameters for PTV and OARs of the three plans in 25 patients (total 75 plans). The mean volume of PTV was 146.559 cc (range: 70.51–318.48 cc). For PTV, the D2%, D50%, and D98% values in TD were significantly better than other plans (\(p < 0.01\)). HT provided for better dose CI (\(p < 0.05\)) and coverage (%) than others. The HI values were similar between the three plans (\(p > 0.05\)). The mean volume of the bladder was 265.515 cc (range: 72.53–494.25 cc), the rectum was 83.914 ± 46.148 cc (range: 35.32–220.29 cc), and the bowel was 1375.541 cc (range: 720.13–3258 cc). The hybrid TH/TD plans provided statistically significant sparing for both the bladder and rectum at all V50(%), V35(%), and V25(%) values (\(p < 0.01\)). At the same rectum and bladder, the V15(%) value of the hybrid TH/TD plan is more advantageous than TH and TD plans. The right femoral head and left femoral head V5% doses were statistically significantly higher in the hybrid TH/TD plan compared to TH and TD (\(p < 0.001\)). We found no significant difference for the bowel V5% and penile bulb V95% among the three plans (\(p > 0.05\)). But bowel V5% and penile bulb V95% hybrid TH/TD plan value was the lowest value when compared with other plans. A comparison of axial and sagittal dose distribution of LPC patients for TH, TD, and hybrid TH/TD plan is shown in Figure 1.

4 | DISCUSSION

The prostate is located below the bladder and in front of the rectum and gastrointestinal and genitourinary toxicity may occur in hypo-fractionated RT applications to prostate cancer.27 In prostate RT, toxicity is related to
TABLE 2  Dose–volume histogram (DVH) parameters (mean ± standard deviation) for planning target volume (PTV) and organs at risk (OARs) with p-values for comparison of Tomo-Helical (TH) and Tomo-Direct (TD)

| Parameters  | Unit       | Tomo-Helical        | Tomo-Direct        | p-Value Tomo-H versus Tomo-D |
|------------|------------|---------------------|---------------------|-----------------------------|
| PTV Vol    | cc         | 146.559 ± 51.446    | 146.559 ± 51.446    |                             |
| PTV D2%    | Gy         | 71.385 ± 0.372      | 71.111 ± 0.334      | <0.001                      |
| PTV D98%   | Gy         | 70.312 ± 0.190      | 70.276 ± 0.124      | 0.037                       |
| PTV D50%   | Gy         | 70.885 ± 0.311      | 70.742 ± 0.283      | 0.003                       |
| CI         |            | 1.400 ± 0.101       | 1.413 ± 0.138       | 0.047                       |
| HI         |            | 1.032 ± 0.006       | 1.149 ± 0.602       | 0.430                       |
| Coverage(%)|            | 99.501 ± 0.423      | 99.332 ± 0.586      | 0.050                       |
| Bladder Vol| cc         | 265.515 ± 120.05    | 265.515 ± 120.05    |                             |
| V50(%)     | Gy         | 25.600 ± 21.092     | 26.496 ± 21.191     | <0.001                      |
| V35(%)     | Gy         | 39.305 ± 21.191     | 40.219 ± 21.417     | <0.001                      |
| V25(%)     | Gy         | 49.403 ± 20.534     | 50.018 ± 20.367     | 0.010                       |
| V15(%)     | Gy         | 60.884 ± 15.169     | 59.056 ± 17.823     | 0.221                       |
| Rectum     |            |                     |                     |                             |
| Rectum Vol | cc         | 83.914 ± 46.148     | 83.914 ± 46.148     |                             |
| V50(%)     | Gy         | 51.301 ± 9.909      | 51.170 ± 11.609     | 0.069                       |
| V35(%)     | Gy         | 61.184 ± 6.305      | 61.529 ± 6.569      | 0.333                       |
| V25(%)     | Gy         | 65.897 ± 4.271      | 65.855 ± 5.326      | 0.882                       |
| V15(%)     | Gy         | 69.475 ± 1.772      | 69.081 ± 2.724      | 0.033                       |
| R Femur    |            |                     |                     |                             |
| V5(%)      | Gy         | 25.830 ± 4.834      | 26.180 ± 6.51       | 0.326                       |
| L Femur    |            |                     |                     |                             |
| V5(%)      | Gy         | 25.818 ± 5.716      | 27.148 ± 7.091      | 0.001                       |
| Penil Bulb |            |                     |                     |                             |
| V95(%)     | Gy         | 45.788 ± 21.246     | 45.457 ± 20.924     | 0.667                       |
| Bowel      |            |                     |                     |                             |
| Bowel Vol  | cc         | 1375.541 ± 1037.756 | 1375.541 ± 1037.756 |                             |
| V5(%)      | Gy         | 2.598 ± 1.746       | 2.66 ± 1.983        | 0.12                        |

Abbreviations: CI, conformity index; Dxx(%), dose incident on xx% structure volume; Gy, gray; HI, homogeneity index; L femur, left femoral head; R Femur, right femoral head; Vol, volume; Vxx(%)Gy, % volume of structure receiving a dose of xx Gy.

the volume irradiated. In this study, we obtained hypofractionated RT plans by using the planning options in two different modes of (TH and TD) separately and together with a certain combination in the HDR tomotherapy. We chose lateral gantry angles for TD to reduce the rectum and bladder dose while creating a hybrid combination. While determining the lateral angles, we tried to choose them according to the anatomy of the patients by using our clinical experience. While generating lateral gantry angles, we encountered an increase in femoral head doses. There are few data to explain femoral toxicity when higher doses are given to small volumes of the femoral heads. Generally, tolerance of entire femoral heads was limit to V50 Gy < 5%. We tried different fraction combinations for the hybrid plans. We have seen that approximately two-thirds of the ratio of TH and one-third of the TD hybrid plan provides a significant reduction in the bladder and rectum doses. In this way, we were able to limit V50 Gy < 5% without increasing the femoral head dose too much.

There are different types of cancer studies with clinical and dosimetrically outcomes reported in patients treated with hybrid RT. Balaji et al. showed the best treatment plan combination would be achieved with 70%–80% 3D-IMRT and 20%–30% arc in the hybrid breast RT. Similarly, Venjakob et al. determined that the hybrid VMAT technique (combination with 80% 3D-CRT/20% VMAT) has positive advantages in RT of breast cancer.
**TABLE 3** Dose–volume histogram (DVH) parameters (mean ± standard deviation) for planning target volume (PTV) and organs at risk (OARs) with p-values for comparison of Tomo-Helical (TH) and hybrid plans

| Parameters     | Unit          | Tomo-Helical | Hybrid (45 Gy/25 Gy) | p-Value |
|----------------|---------------|--------------|----------------------|---------|
| PTV Vol        | 146.559 ± 51.446 (cc) |             |                      |         |
| PTV D2%        | Gy            | 71.385 ± 0.372 | 71.188 ± 0.767      | 0.259   |
| PTV D98%       | Gy            | 70.312 ± 0.190 | 70.506 ± 0.394      | 0.002   |
| PTV D50%       | Gy            | 70.885 ± 0.311 | 70.971 ± 0.287      | 0.170   |
| CI             |               | 1.400 ± 0.101  | 2.086 ± 0.589       | <0.001  |
| HI             |               | 1.032 ± 0.006  | 1.0344 ± 0.104      | 0.311   |
| Coverage(%)    |               | 99.501 ± 0.423 | 99.488 ± 0.481      | 0.819   |
| Bladder Vol    | 265.515 ± 120.05 (cc) |             |                      |         |
| V50(%)         | Gy            | 25.600 ± 21.092 | 22.185 ± 19.041   | <0.001  |
| V35(%)         | Gy            | 39.305 ± 21.191 | 34.673 ± 20.866   | <0.001  |
| V25(%)         | Gy            | 49.403 ± 20.534 | 44.937 ± 21.128   | <0.001  |
| V15(%)         | Gy            | 60.884 ± 15.169 | 57.795 ± 17.254   | 0.001   |
| Rectum Vol     | 83.914 ± 46.148 (cc) |             |                      |         |
| V50(%)         | Gy            | 51.301 ± 9.909  | 41.874 ± 14.421    | <0.001  |
| V35(%)         | Gy            | 61.184 ± 6.305  | 54.156 ± 10.467    | <0.001  |
| V25(%)         | Gy            | 65.897 ± 4.271  | 62.573 ± 7.476     | <0.001  |
| V15(%)         | Gy            | 69.475 ± 1.772  | 68.723 ± 3.157     | 0.009   |
| R Femur V5(%)  | Gy            | 25.830 ± 4.834  | 39.646 ± 7.438     | <0.001  |
| L Femur V5(%)  | Gy            | 25.818 ± 5.716  | 39.723 ± 5.222     | <0.001  |
| Penile Bulb V95(%) | Gy       | 45.788 ± 21.246 | 44.705 ± 21.156   | 1.00    |
| Bowel Vol      | 1375.541 ± 1037.756 (cc) |             |                      |         |
| V5(%)          | Gy            | 2.598 ± 1.746   | 2.303 ± 1.265      | 0.323   |

The study of Zhao et al. showed that the target dose HI and CI was better and critical organ doses decreased by the hybrid IMRT/VMAT technique compared to other techniques for treatment of nasopharyngeal cancer.32 Silva et al. presented the clinical application of the hybrid Rapid Arc in patients with locally advanced lung cancer. Hybrid Rapid Arc plans were created with the combination of static (60%) and Rapid Arc (40%) beams and showed advantages for reducing the OARs dose.33 We tried different fraction combinations for the hybrid plans in this study. We conclude that 45 Gy/18 fxs for TH and 25 Gy/10 fxs for TD is the best combination.

The number of studies involving hybrid RT of prostate cancer is limited in the literature. The study of Amaloo et al. compared VMAT plans with hybrid plans in prostate patients.34 They determined that hybrid plans yielded fewer rectum and bladder doses in almost all cases. Similarly, in our study, we found statistically significant lower doses in the rectal and bladder in hybrid plans. Penile bulb and bowel doses were lower in hybrid plans too. The study of Robar et al. stated that the Hybrid-Arc method provides various advantages in different anatomical regions and increases PTV dose homogeneity for prostate treatment.35 In a study examining prostate cancer hybrid IMRT and volumetric modulated arc treatment plans, the 25% IMRT technique increased target dose homogeneity and provided rectum protection.36 In the current study, as we used beams containing lateral gantry angles used when trying to lower bladder and rectum doses, the hybrid TH/TD plan CI value was statically significantly higher than TH and TD ($p < 0.001$). Also, all planning methods (TD, TH, and hybrid) provided good coverage (%). There was a significant increase in femoral head V5% dose in hybrid plans compared to TH and TD plans ($p < 0.001$). Similarly, Amaloo et al. determined that there was an increase in
TABLE 4  Dose–volume histogram (DVH) parameters (mean ± standard deviation) for planning target volume (PTV) and organs at risk (OARs) with p-values for comparison of Tomo-Direct (TD) and hybrid plans

| Parameters       | Unit       | Tomo-Direct | Hybrid (45 Gy/25 Gy) | p-Value |
|------------------|------------|-------------|----------------------|---------|
| PTV              |            |             |                      |         |
| PTV Vol          | cc         | 146.559 ± 51.446 | 71.188 ± 0.767       | 0.004   |
| PTV D2%          | Gy         | 71.111 ± 0.334 | 71.188 ± 0.767       | 0.004   |
| PTV D98%         | Gy         | 70.276 ± 0.124 | 70.506 ± 0.394       | <0.001  |
| PTV D50%         | Gy         | 70.742 ± 0.283 | 70.971 ± 0.287       | <0.001  |
| CI               |            | 1.413 ± 0.138 | 2.086 ± 0.589        | <0.001  |
| HI               |            | 1.149 ± 0.602 | 1.034 ± 0.104        | 0.222   |
| Coverage(%)      |            | 99.332 ± 0.586 | 99.488 ± 0.481       | 0.002   |
| Bladder          |            |             |                      |         |
| Bladder Vol      | cc         | 265.515 ± 120.05 | 22.185 ± 19.041      | <0.001  |
| V50(%)           | Gy         | 26.496 ± 21.191 | 34.673 ± 20.866      | <0.001  |
| V35(%)           | Gy         | 40.219 ± 21.417 | 44.937 ± 21.128      | <0.001  |
| V25(%)           | Gy         | 50.018 ± 20.367 | 62.573 ± 7.476       | <0.001  |
| V15(%)           | Gy         | 59.056 ± 17.823 | 57.795 ± 17.254      | 0.013   |
| Rectum           |            |             |                      |         |
| Rectum Vol       | cc         | 83.914 ± 46.148 | 41.874 ± 14.421      | <0.001  |
| V50(%)           | Gy         | 51.170 ± 11.609 | 54.156 ± 10.467      | <0.001  |
| V35(%)           | Gy         | 61.529 ± 6.569 | 62.573 ± 7.476       | <0.001  |
| V25(%)           | Gy         | 65.855 ± 5.326 | 62.573 ± 7.476       | <0.001  |
| V15(%)           | Gy         | 69.081 ± 2.724 | 68.723 ± 3.157       | 0.065   |
| R Femur          |            |             |                      |         |
| V5(%)            | Gy         | 26.180 ± 6.51  | 39.646 ± 7.438       | <0.001  |
| L Femur          |            |             |                      |         |
| V5(%)            | Gy         | 27.148 ± 7.091 | 39.723 ± 5.222       | <0.001  |
| Penile Bulb      |            |             |                      |         |
| V95(%)           | Gy         | 45.457 ± 20.924 | 44.705 ± 21.156      | 0.788   |
| Bowel            |            |             |                      |         |
| Bowel Vol        | cc         | 1375.541 ± 1037.756 | 2.66 ± 1.983       | 0.201   |
| V5(%)            | Gy         | 2.66 ± 1.983 | 2.303 ± 1.265        | 0.201   |

the maximum doses of the femoral heads in the hybrid VMAT plans.34

There are some studies in the literature comparing TH and TD plans of the tomotherapy system. Davidson et al. compared seven-angle static IMRT plans with TH plans for prostate patients and found conventional IMRT plans were similar to TH.37 In the study of Murai et al., they compared five static gantry angled TD plans with TH plans and found the dose to the rectum in TD plans was significantly higher than TH plans.20 In our study, the rec-
tum doses were similar between TH and TD but bladder V50 and V35 doses were found to be statistically signif-
ically lower in TH plans compared to TD (p < 0.001).

There are several limitations of our study. First of all, we used a small number of patient dosimetric data. The other limitation of this study was similar tomotherapy plans were obtained with fixed gantry angle, iterations, and optimization criteria. Considering that each patient has different PTV, OARs, and anatomical deviations, a specific treatment plan could not be obtained for each patient. Besides, creating and evalu-
ating hybrid plans can cause extra workload for clinics (planning time, delivery quality assurance, etc.). In addition, more research is required on the clinical outcomes of LPC patients treated with hybrid TH/TD. In order to overcome these limitations, large-scale clinical studies can be carried out with a large number of patients and special plans can be made for each patient. Clinics can start the application with the determined standard data without extra workload.

5 | CONCLUSION

In this study, we presented a new hybrid delivery method for LPC in HDA tomotherapy. The use of lateral beams
in the TH in the hybrid model was a unique approach. Our study showed the advantages of reducing bladder and rectal doses of the hybrid TH/TD method compared to the TH and TD methods. This study may shed light on studies aimed at reducing critical organ dose in hypofractionated prostate RT, which is expected to become widespread in the future.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS
Conception and design: Sibel Karaca; Administrative support: Aylin Fidan Korcum Şahin; Provision of study materials or patients: Sibel Karaca, Timur Koca, and Ismail Hakkı Sarpün; Collection and assembly of data: Sibel Karaca; Data analysis and interpretation: Sibel Karaca, Nina Tunçel, and Timur Koca; Manuscript writing: Sibel Karaca; Final approval of manuscript: All authors.

ETHICAL APPROVAL
Our study was approved by the Akdeniz University Faculty of Medicine Ethics Committee of Clinical Trials (2020 – KAEK-813). The study was a retrospective review so subject informed consent was not obtained.

REFERENCES
1. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.
2. Barelkowski T, Wust P, Kaul D, et al. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy. Strahlenther Onkol. 2020;196(3):229-242.
3. Viani GA, Viana BS, Martin JE, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer. 2016;122(13):2004-2011.
4. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429-1437.
5. Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE. Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009;93:185-191.
6. Amin A, El Sayed S, Ezzat A. Dosimetric evaluation of advanced radiotherapy techniques in treating patients with prostatic cancer. Research in Oncology. 2017;13(2):40-45.
7. Luxton G, Hancock SL, Boyer AL. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2004;59(1):267-284.
8. Vlachaki MT, Teslow TN, Amosson C, Uy NW, Ahmad S. IMRT versus conventional 3DCRT on prostate and normal tissue dosimetry using an endorectal balloon for prostate immobilization. Med Dosim. 2005;30(2):69-75.
9. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980-988.
10. Beckendorf V, Gueif S, Le Prise E, et al. 70Gy versus 80Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056-1063.
11. Arcangeli S, Scorsetti M, Alongi F. Will SBRT replace conventional radiotherapy in patients with low intermediate risk prostate cancer? A review. Crit Rev Oncol Hematol. 2012;84:101-108.
KARACA ET AL.

12. Bhide S, Nutting C. Recent advances in radiotherapy. BMC Med. 2010;8:25.
13. Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(4):904-912.
14. Kupelian PA, Thakkar VV, Khuntia D, et al. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005;63(5):1463-1468.
15. Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):325-333.
16. Macias V, Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009;11:437-445.
17. Serra M, Ametrano G, Borzillo V, et al. Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer. Medicine. 2020;99(50):e23574.
18. Yartsev S, Kron T, Van Dyk J. Tomotherapy as a tool in image-guided radiation therapy (IGRT): theoretical and technological aspects. Biomed Imaging Interv J. 2007;3(1):e16.
19. Hong CS, Kim MJ, Kim J, et al. Feasibility of hybrid tomohelical- and tomodirect-based volumetric gradient matching technique for total body irradiation. Radiat Oncol. 2019;14:233.
20. Franco P, Ricardi U. TomoDirect to deliver static angle tomotherapy treatments. J Nucl Med Radiat Ther. 2012;35.
21. Kraus KM, Kampfer S, Wilkens JJ, et al. Helical tomotherapy: comparison of Hi-ART and radiact clinical patient treatments at the Technical University of Munich. Sci Rep. 2020;10:4928.
22. Gay HA, Barthold HJ, O’Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a radiation therapy oncology group consensus panel atlas. Int J Radiat Oncol Biol Phys. 2012;83(3):e353-62.
23. Lee R, James W, Dignam J, et al. NRG oncology RTOG 0415: a randomized phase III non-inferiority study comparing two fractionation schemes in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2.
24. ICRU Report 83, Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT). J ICRU. 2010;10(1):1-106.
25. Cao T, Dai Z, Ding Z, Li W, Quan H. Analysis of different evaluation indexes for prostate stereotactic body radiation therapy plans: conformity index, homogeneity index and gradient index. Precis Radiat Oncol. 2019;3:72-79.
26. Di Franco R, Borzillo V, Ravo V, et al. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2017;21(16):3563-3575.
27. Fuentes-Raspall R, Inoriza JM, Rosello-Serrano A, Auñón-Sanz C, Garcia-Martín P, Oliu-Isern G. Late rectal and bladder toxicity following radiation therapy for prostate cancer: predictive factors and treatment results. Rep Pract Oncol Radiother. 2013;18(5):298-303. PMID: 24416567; PMCID: PMC3863251.
28. Emami B. Tolerance of normal tissue to therapeutic radiation. Rep Radiother Oncol. 2013;1(1):123-127.
29. Balaji K, Yadav P, Balaji Subramanian S, Anu Radha C, Ramasubramanian V. Hybrid volumetric modulated arc therapy for chest wall irradiation: for a good plan, get the right mixture. Phys Med. 2018;52:86-92.
30. Venjakob A, Oertel M, Hering DA, Moustaquis C, Havercamp U, Eich HT. Hybrid volumetric modulated arc therapy for hypofractionated radiotherapy of breast cancer: a treatment planning study. Strahlenther Onkol. 2021;197(4):296-307.
31. Zhao N, Yang R, Jiang Y, Tian S, Guo F, Wang J. A hybrid IMRT/VMAT technique for the treatment of nasopharyngeal cancer. Biomed Res Int. 2015;2015:940102.
32. Silva SR, Surucu M, Steber J, Harkenrider MM, Choi M. Clinical application of a hybrid rapidarc radiotherapy technique for locally advanced lung cancer. Technol Cancer Res Treat. 2017;16(2):224-230.
33. Amaloo C, Nazareth DP, Kumaraswamy LK. Comparison of hybrid volumetric modulated arc therapy (VMAT) technique and double arc VMAT technique in the treatment of prostate cancer. Radiol Oncol. 2015;21(3):291-298.
34. Robar JL, Thomas C. HybridArc: a novel radiation therapy technique combining optimized dynamic arcs and intensity modulation. Med Dosim. 2012;37(4):358-368.
35. Bedford JL, Smyth G, Hanson IM, Tree AC, Dearnaley DP, Hansen VN. Quality of treatment plans and accuracy of in vivo portal dosimetry in hybrid intensity-modulated radiation therapy and volumetric modulated arc therapy for prostate cancer. Radiother Oncol. 2016;120(2):320-326.
36. Davidson MT, Blake SJ, Batchelor DL, Cheung P, Mah K. Assessing the role of volumetric modulated arc therapy (VMAT) relative to IMRT and helical tomotherapy in the management of localized, locally advanced, and post-operative prostate cancer. Int J Radiat Oncol Biol Phys. 2011;80:1550-1558.

How to cite this article: Karaca S, Koca T, Sarpun IH, Tunçel N, Korcum Şahin AF. Hybrid Tomo-Helical and Tomo-Direct radiotherapy for localized prostate cancer. J Appl Clin Med Phy. 2021;22:136–143. https://doi.org/10.1002/acm2.13406